NCCS submitted comments to the Centers for Medicare and Medicaid Services (CMS) on the proposed rule that is intended to “help stabilize the individual and small group markets.” The Affordable Care Act (ACA) has provided health insurance coverage—and therefore access to health care—for many cancer survivors who were previously denied ...

NCCS joined with patient advocacy organizations in the Cancer Leadership Council (CLC) in submitting a letter to Congressional leaders regarding the Affordable Care Act (ACA). In our letter, we urge Congress not to repeal the ACA until specific proposals are identified to replace the ACA. Representing cancer patients, caregivers, and ...

NCCS submitted comments to the Centers for Medicare and Medicaid Services (CMS) on the proposed revisions to the 2017 Physician Fee Schedule. Our comments noted our support for the Oncology Care Model, but acknowledged that only a minority of cancer care providers and cancer patients will be part of this ...

NCCS submitted comments to the Food and Drug Administration (FDA) on the letter representing the agreement between FDA and regulated industry on goals for the re-authorization of the Prescription Drug User Fee Act (PDUFA VI). NCCS participated in the PDUFA stakeholder meetings held over the last year, and we support ...

NCCS submitted comments to the Centers for Medicare and Medicaid Services (CMS) on the proposed rule on the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Our comments focus on the role of consumers in identification, development, and endorsement of quality measures. As health care delivery and payment transition ...

NCCS joined with patient advocacy organizations in the Cancer Leadership Council (CLC) in submitting comments to the Reagan-Udall Foundation regarding the Draft Project Proposal for the Expanded Access Navigator for Individual Patient Access. In our letter, we commend the revisions to guidance documents, FDA educational materials, and the FDA website ...

In 1992, Congress passed the first Prescription Drug User Fee Act (PDUFA), a law that allows the Food and Drug Administration (FDA) to collect fees from drug companies that apply to the FDA for approval to market their drugs for specific medical conditions, e.g., a chemotherapy drug for ALK-positive lung ...

NCCS joined with patient advocacy organizations in the Cancer Leadership Council (CLC) in submitting comments to the Centers for Medicare and Medicaid Services (CMS) on its proposed Part B drug payment demonstration project. Over many years, the CLC has advocated reforms in Medicare reimbursement for cancer care, to support the ...

The Centers for Medicare and Medicaid Services (CMS) announced that they are postponing the release of their Hospital Compare Star Ratings. This is an unfortunate delay, as these ratings will serve as a valuable tool for cancer survivors and their families to have the information necessary to make informed decisions ...

NCCS recently submitted comments on the Senate Finance Committee's "Bipartisan Chronic Care Working Group Policy Options Document" in response to the working group's request for comments on possible policy options outlined in its report. Formed in May 2015, the working group is seeking ideas on how Medicare can improve the ...